Live Feeds
● LIVE Updated 1h ago · 6 sources tracked

Radiopharma companies merge after one receives surprise FDA rejection

Telix Pharmaceuticals is acquiring German radiopharmaceutical biotechnology company ITM in a deal valued at an initial US$1.65 billion. The acquisition follows a surprise FDA rejection for one of the companies. While analysts are "extremely bullish" about the move, Telix stock fell 3% as the deal adds 105.8 million shares. The merger positions Telix as a global leader in the radiopharmaceutical sector, expanding its reach into territory currently held by Novartis.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (6)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Telix Pharmaceuticals is acquiring German radiopharmaceutical biotechnology company ITM.
  • ✓ The initial payment for the acquisition is US$1.65 billion.
  • ✓ The deal adds 105.8 million shares to Telix.
🛡️ Source Corroboration: 6 independent reporting domains (80% confidence) ⏱ Read time: ~2 min

What changed

Telix Pharmaceuticals announced an initial US$1.65 billion acquisition of German firm ITM.

Live updates

  1. Telix Pharmaceuticals to acquire ITM for initial US$1.65 billion

    Telix Pharmaceuticals is acquiring German radiopharmaceutical biotechnology company ITM in a deal valued at an initial US$1.65 billion. The acquisition follows a surprise FDA rejection for one of the companies. While analysts are "extremely bullish" about the move, Telix stock fell 3% as the deal adds 105.8 million shares. The merger positions Telix as a global leader in the radiopharmaceutical sector, expanding its reach into territory currently held by Novartis.

    Why it matters

    Radiopharmaceuticals combine radioactive isotopes with targeting molecules to treat or image specific diseases. This acquisition allows Telix to scale its global infrastructure and compete more directly with established industry giants.

    What is confirmed

    • Telix Pharmaceuticals is acquiring German radiopharmaceutical biotechnology company ITM.
    • The initial payment for the acquisition is US$1.65 billion.
    • The deal adds 105.8 million shares to Telix.

    Still unconfirmed

    • The merger occurred after one of the companies received a surprise FDA rejection.
    • Telix stock fell 3% following the deal announcement.
    • Analysts are "extremely bullish" regarding Telix entering Novartis' territory.

    What to watch next

    • Confirmation of which specific drug received the FDA rejection
    • Final valuation of the deal beyond the initial payment
    • Market response to the issuance of 105.8 million new shares
    Sources used for this update (6)
    1. www.rttnews.com — Biotech & Pharma News, Stocks, FDA Decision, Clinical Trials - RTTNews
    2. statnews.com — Radiopharma companies merge after one receives surprise FDA rejection
    3. Fierce Biotech — Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
    4. TradingView — TLX: US$1.65B acquisition creates a global radiopharmaceutical leader with major growth potential
    5. TechStock² — Telix’s US$1.65 Billion ITM Deal Adds 105.8 Million Shares as Stock Falls 3%
    6. Yahoo Finance Australia — Australian Shares Flat; Telix Pharmaceuticals to Acquire German Radiopharmaceutical Biotechnology Company for Initial $1.65 Billion Payment
    confidence 80%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community